1Mclachlin CM. Human papillomovirus in cervical ner plasia. Role, risk factors and implications[J]. Clim Lab Med, 2000, 20(12): 257-270.
2Manoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. [J]. Int J Cancer,2004, 111(2):278-285.
3Fausch SC, Da Silva DM, Kast WM. Heterologous papillomavirus rirus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells[J]. Vaccine, 2005, 23(14):1720-1729.
4Frazer IH, Thomas R, Zhou J, et al. Potential strategies utilized by papillomavirus to evade host immunity[J]. Immunol Rev, 1999, 168:131-132.
1Lonky NM, Sadeghi M, Tsadik GW, et al. The clinical significance of the poor correlation of cervical dysplasia and cervical malignancy with referral cytologic results. Am J Obstet Gynecol,1999,181:560-566.
2Rokyta Z. Diagnostic reliability of prebioptic methods in the prediction of a histological basis of cervical lesions and its correlation with accuracy of colposcopically directed biopsy in patients with cervical neoplasia. Eur J Gynecol Oncol,2000,21:484-486.
